Home > Press > Singapore Continues to Attract Top Scientific Talents
Abstract:
Offers Investigatorship Awards up to US$500,000 to Outstanding Young Scientists of all Nationalities to Undertake Independent Research in Singapore
Singapore continues to thrive as a vibrant location for scientific talent. Significant efforts and resources have been committed to attract and develop talent. Singapore adopts a pro-international and pro-local approach. A dynamic research environment, robust ethical framework, strict laws for the protection of intellectual property rights (Note 1) and quality of life, are some of the key reasons why a growing number of scientists are drawn to Singapore.
Note 1: Singapore cited as the best location in Asia for the protection
of intellectual property rights. (Source: The International
Property Rights Index (2007))
Over the past five years, Singapore has attracted an impressive list of internationally prominent scientists to lead the nation's biomedical sciences research and development efforts. (Please refer to Annex A for a list of distinguished scientists in Singapore.)
In continuing its efforts to attract talent, Singapore's Agency for Science, Technology & Research (A-STAR) launched A-STAR Investigatorships, a prestigious competitive award aimed at young international postdoctoral fellows who have demonstrated strong ability and creativity in research. Recipients of the award will be given an independent position at one of A-STAR's research institutes and can receive funding of up to US$500,000 per year.
"We invite and encourage the best young scientists of all nationalities to carry out cutting-edge research in Singapore. Recipients of A-STAR Investigatorships will enjoy generous funding, excellent facilities and infrastructure at Biopolis, as well as have the opportunity to be mentored by some of the world's most highly regarded biomedical researchers," said Dr. Andre Wan, Deputy Executive Director, Biomedical Research Council, A-STAR.
This year's call for proposals is in the areas of molecular and cell biology, genetics and genomics research relevant to human diseases and health. Applications are open and the deadline for submission is 31 May 2007.
SINGAPORE, A VIBRANT NODE IN THE INTERNATIONAL RESEARCH & DEVELOPMENT LANDSCAPE
A-STAR investigators will join a vibrant and rapidly growing community of more than 900 scientists and postdoctoral fellows from over 50 countries at the Biopolis, Singapore's premier biomedical research hub.
Partnerships and Collaborations
A-STAR is well connected to the international biomedical research community. Scientists at the institutes work closely with partners in the U.S. (e.g. UCSD, UIUC, UWash, MIT, Fred Hutch CRC), Europe (e.g. Karolinska Institute, Imperial College, Cambridge University, Dundee University, French Atomic Energy Commission) and Australasia (e.g. Australian National University, RIKEN in Japan) on research projects, collaborations and PhD training programs. A-STAR also hosts key international scientific conferences (e.g. Keystone, European Molecular Biology Organization, American Association for Cancer Research) and visits by distinguished scientists including many Nobel laureates.
The National University of Singapore (NUS) and Nanyang Technological University have also been successfully forging international partnerships. Duke University and NUS set up a Graduate Medical School (GMS) in Singapore to nurture clinician-scientists. The GMS will accept its first batch of students in August 2007 and will be awarding joint MD degrees from Duke and NUS.
Translational and Clinical Research
A-STAR works closely with the National Medical Research Council of the Singapore Ministry of Health to develop and strengthen research collaborations and programs between scientists at the Biopolis and the clinical community in hospitals and disease centers. The aim is to translate basic scientific discoveries and innovative technologies into potential therapies and diagnostics that will be applicable to major health conditions such as cancer, cardiovascular diseases, neurological disorders, infectious diseases and eye diseases.
"The scientists of today are incredibly mobile. They can choose to work anywhere in the world. Those who have selected Singapore have told us it is due to a combination of three reasons: steady funding, good facilities and exciting colleagues. We hope the A-STAR Investigatorships will extend this winning combination to the next generation of scientific leaders and persuade them to consider building their careers in Singapore," said Dr. Wan.
To obtain more information, please visit the Singapore Pavilion at booth number 2533.
####
About Agency for Science, Technology and Research and EDB Singapore
ANNEX A
LIST OF DISTINGUISHED SCIENTISTS IN SINGAPORE
Industry
Name From Designation in Other information
Singapore
Alex Matter (Dr.) Novartis Director, Novartis Led the
Institute for development of
Tropical Diseases Gleevec,
Novartis' cancer
therapeutic
blockbuster drug.
Alan Colman (Dr.) U.K.-based PPL Chief Executive Well known for
Therapeutics, a Officer, ES Cell his work with the
spin-off from the International Roslin Institute
Roslin Institute to clone Dolly
the sheep.
Scientific Leaders at A-STAR's Biomedical Research Council
Name From Designation in Other information
Singapore
Sydney Brenner Salk Institute -- Scientific 2002 Nobel prize
(Dr.) of Biological Advisor to in Physiology or
Studies Chairman, Medicine for
A-STAR establishing C.
-- Chairman, elegans as a novel
Biomedical experimental
Research model organism to
Council link genetic
analysis to cell
division,
differentiation
and organ
development.
David Lane University of -- Executive One of the
(Dr. Sir) Dundee Deputy Chairman, scientists
Biomedical credited with
Sciences and the landmark
Technology, discovery of the
Biomedical cancer gene p53.
Research Founder of
Council Cyclacel, a
-- Executive Scottish biotech
Director, company.
Institute of
Molecular and
Cell Biology
-- Chief Executive
Officer,
Experimental
Therapeutics
Centre
Edward Holmes University of -- Executive Expert on
(Dr.) California San Deputy Chairman, translational
Diego Clinical- research and
Translational academic medicine.
Sciences,
Biomedical
Research Council.
-- Executive
Chairman, National
Medical Research
Council,
Ministry of Health
Research Institutes
Name From Designation in Other information
Singapore
Edison Liu(Dr.) National Cancer Executive Expert on breast
Institute Director, Genome cancer research.
Institute of
Singapore
Jackie Ying(Dr.) Massachusetts Executive Expert on
Institute of Director, nanotechnology and
Technology Institute of its use in
Bioengineering & biotechnology,
Nanotechnology medical and
chemical sciences.
Judith Swain(Dr.) University of Executive Expert on creating
California San Director, models to
Diego Singapore understand the
Institute of genetic basis of
Clinical Sciences cardiovascular
development and
disease.
Neal Copeland & National Cancer Principal Renowned cancer
Nancy Jenkins Institute Investigators, geneticists who
(Drs.) Institute of are among the
Molecular and Cell world's most
Biology frequently-cited
scientists.
Philip Ingham University of Principal Expert on
(Dr.) Sheffield Investigator, developmental
Institute of genetics
Molecular and and cell-to-cell
Cell Biology communication.
Jean Paul Institut Curie Principal Expert on cell
Thiery Dr.) Investigator, adhesion and
Institute of migration studies.
Molecular and
Cell Biology
Yoshiaki Ito University of Principal Expert on RUNX
(Dr.) Kyoto Investigator, genes, a major
Institute of tumor suppressor
Molecular and associated with
Cell Biology gastric cancer.
and the
National
University of
Singapore
Consortia
Name From Designation in Other information
Singapore
George Radda Department of Chairman, Expert on magnetic
(Dr.Sir) Physiology, Singapore resonance in
Anatomy and Bioimaging medicine.
Genetics, Consortium
University
of Oxford
Philippe College de Chairman, Expert on
Kourilsky France Singapore molecular
(Dr.) Immunology immunology and
Network tumor immunity.
Roger Pedersen University of Chairman, Expert on stem
(Dr.) Cambridge Singapore Stem cell.
Cell
Consortium
Axel Ullrich Oversees the Director, Founder of
(Dr.) molecular Singapore numerous biotech
biology OncoGenome companies
department, Project including Sugen
Max Planck and U3.
Institute,
Germany
For media enquiries, please contact Ruder Finn.
Contacts:
Kim Hamelburg
Senior Associate
Ruder Finn Binder (Boston)
Tel: +1-781-559-0429
HP: +1-202-577-8227
Email:
Rae Chew
Senior Consultant
Ruder Finn Asia (Singapore)
HP: +65-9823-7722
Email:
Copyright © PR Newswire Europe Limited
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
| Related News Press |
Announcements
Rice membrane extracts lithium from brines with greater speed, less waste October 3rd, 2025
Researchers develop molecular qubits that communicate at telecom frequencies October 3rd, 2025
Next-generation quantum communication October 3rd, 2025
"Nanoreactor" cage uses visible light for catalytic and ultra-selective cross-cycloadditions October 3rd, 2025
Grants/Sponsored Research/Awards/Scholarships/Gifts/Contests/Honors/Records
Researchers tackle the memory bottleneck stalling quantum computing October 3rd, 2025
New discovery aims to improve the design of microelectronic devices September 13th, 2024
Physicists unlock the secret of elusive quantum negative entanglement entropy using simple classical hardware August 16th, 2024
|
|
||
|
|
||
| The latest news from around the world, FREE | ||
|
|
||
|
|
||
| Premium Products | ||
|
|
||
|
Only the news you want to read!
Learn More |
||
|
|
||
|
Full-service, expert consulting
Learn More |
||
|
|
||